ReviewJournal of neuroscience research2017
Defective phosphoinositide metabolism in autism.
Review in Journal of neuroscience research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Comparative Lipidomic Profiling of Camel and Cow Milk from a Shared Semi-Desert Pasture: Implications for Camel Adaptation to Arid Environments.Molecules (Basel, Switzerland) · 2026Article
- Parental and professional perspectives on prenatal psychosocial experiences perceived to be linked to autism spectrum disorder: a qualitative content analysis study.BMC psychiatry · 2026Article
- Inositol and PIP2/PIP3 Ratio: At the Crossroad of the Biodynamic Interface Between Cells and Their Microenvironment.Biomolecules · 2025Review
- Lipidomic profiling of mouse brain and human neuron cultures reveals a role forScience translational medicine · 2025Article
- Copy number variations in autistic children.Biomedical reports · 2024Article
- Study of Pragmatic Skills of Persian-speaking Adults with Autism Spectrum Disorder Based on the Persian Version of Montreal Protocol for the Evaluation of Communication (P.M.E.C.).Medical journal of the Islamic Republic of Iran · 2024Article
- Dysregulated phosphate metabolism in autism spectrum disorder: associations and insights for future research.Expert reviews in molecular medicine · 2023Review
- Role of Lysosomal Cholesterol in Regulating PI(4,5)PAdvances in experimental medicine and biology · 2023Article
- Comparative study of the relationship between pregnancy and childbirth factors and autism in healthy children and children with autism.Journal of education and health promotion · 2023Article
- Comparative Analysis of Testicular Histology and lncRNA-mRNA Expression Patterns Between Landes Geese (Frontiers in genetics · 2021Article
- Striking a balance: PIPExploration of neuroprotective therapy · 2021Article
- Cell Type-Specific Gene Network-Based Analysis Depicts the Heterogeneity of Autism Spectrum Disorder.Frontiers in cellular neuroscience · 2020Article
- Review
- Recent advances in understanding phosphoinositide signaling in the nervous system.F1000Research · 2019Review
- Biofluid lipidome: a source for potential diagnostic biomarkers.Clinical and translational medicine · 2017Review
- Dysregulation of mRNA Localization and Translation in Genetic Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Phosphoinositides are essential components of lipid membranes and crucial regulators of many cellular functions, including signal transduction, vesicle trafficking, membrane receptor localization and activity, and determination of membrane identity. These functions depend on the dynamic and highly regulated metabolism of phosphoinositides and require finely balanced activity of specific phosphoinositide kinases and phosphatases. There is increasing evidence from genetic and functional studies that these enzymes are often dysregulated or mutated in autism spectrum disorders; in particular, phosphoinositide 3-kinases and their regulatory subunits appear to be affected frequently. Examples of autism spectrum disorders with defective phosphoinositide metabolism are fragile X syndrome and autism disorders associated with mutations in the phosphoinositide 3-phosphatase tensin homolog deleted on chromosome 10 (PTEN), but recent genetic analyses also suggest that select nonsyndromic, idiopathic forms of autism may have altered activity of phosphoinositide kinases and phosphatases. Isoform-specific inhibitors for some of the phosphoinositide kinases have already been developed for cancer research and treatment, and a few are being evaluated for use in humans. Altogether, this offers exciting opportunities to explore altered phosphoinositide metabolism as a therapeutic target in individuals with certain forms of autism. This review summarizes genetic and functional studies identifying defects in phosphoinositide metabolism in autism and related disorders, describes published preclinical work targeting phosphoinositide 3-kinases in neurological diseases, and discusses the opportunities and challenges ahead to translate these findings from animal models and human cells into clinical application in humans. © 2016 Wiley Periodicals, Inc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.